Intracerebral hemorrhage secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(10 intermediate revisions by the same user not shown)
Line 5: Line 5:


==Overview==
==Overview==
Effective measures for the secondary prevention of intracerebral hemorrhage include life style modification, treatment of modifiable risk factors such as blood pressure control and anticoagulation medication avoidance, and enforcing the measures to prevent the complications.<ref name="ASA/AHA-ICH-Guid2" /><ref name="ASA/AHA-Primary-Prevention-Guid" /><ref name="DOACs" /><ref name="pmid21309657" /><ref name="Eckman" /><ref name="pmid20539816" /><ref name="pmid23983842" />


==Secondary prevention==
==Secondary prevention==
===Life style modification===
===Prevention of recurrent ICH ===
Life style modification measures which may help reduce the risk of intracerebral hemorrhage recurrent may include:
====Life style modification====
Life style modification measures which may help reduce the risk of intracerebral hemorrhage recurrent may include:<ref name="ASA/AHA-ICH-Guid2" /><ref name="ASA/AHA-Primary-Prevention-Guid">2014 AHA/ASA Guidelines for the Primary Prevention of Stroke http://stroke.ahajournals.org/content/early/2014/10/28/STR.00000000000000467  Accessed on November 17, 2016</ref>
*Eating healthy balanced diet
*Eating healthy balanced diet
*Smoking cessation
*Smoking cessation
*Decreased alcohal intake
*Decreased alcohol intake
*Improved support from health care providers & care takers
*Improved support from health care providers & care takers
*Patient education (involvement in BP monitoring to improve adherence to therapy)
*Patient education (involvement in BP monitoring to improve adherence to therapy)
===Prevention of recurrent ICH ===


==== Blood pressure control ====
==== Blood pressure control ====
Receive early treatment targeted to an [[SBP]] level <140 mmHg to improve the chances of achieving better functional recovery
Receive early treatment targeted to an [[SBP]] level <140 mmHg to improve the chances of achieving better functional recovery.<ref name="ASA/AHA-ICH-Guid2" />


====Restarting anticoagulation====
====Restarting anticoagulation====
Restarting anticoagulation should be avoided, UNLESS the risk of [[ischemic stroke]] is MUCH HIGHER than that of recurrent ICH.
Restarting anticoagulation should be avoided, UNLESS the risk of [[ischemic stroke]] is MUCH HIGHER than that of recurrent ICH.<ref name=DOACs>Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review http://dx.doi.org/10.1016/j.thromres.2015.05.001 Accessed on December 1, 2016</ref><ref name="pmid21309657">{{cite journal| author=Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al.| title=Apixaban in patients with atrial fibrillation. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 9 | pages= 806-17 | pmid=21309657 | doi=10.1056/NEJMoa1007432 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21309657  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21803760 Review in: Evid Based Med. 2011 Dec;16(6):187-8]  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21502641 Review in: Ann Intern Med. 2011 Apr 19;154(8):JC4-3]</ref><ref name=Eckman> Eckman, Mark H., et al. "Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis." Stroke 34.7 (2003): 1710-1716.</ref>
* In AF patients with warfarin-associated lobar ICH or suspected [[Cerebral amyloid angiopathy|CAA]], the risk ICH recurrence seems higher than [[Thromboembolic event|thromboembolic events]]. Therefore, the best management is to discontinue [[Warfarin|warfarin therapy.]]
* In AF patients with warfarin-associated lobar ICH or suspected [[Cerebral amyloid angiopathy|CAA]], the risk ICH recurrence seems higher than [[Thromboembolic event|thromboembolic events]]. Therefore, the best management is to discontinue [[Warfarin|warfarin therapy.]]
 
**In patients with lobar ICH and [[CHA2DS2-VASc Score|CHADS2 VASc score]] > 5
*In patients with lobar ICH and [[CHADS2 score]] ≥5
*** [[Left atrial appendage|LAA closure]] is a viable option  
** LAA closure is a viable option  
***If [[Left atrial appendage|LAA]] is not feasible [[Oral anticoagulation therapy|oral anticoagulation (OAC)]] is considered
**If LAA is not feasible [[Oral anticoagulation therapy|oral anticoagulation (OAC)]] is considered
***The use of DOACS (e.g. [[Apixaban]]) might be an alternative to [[warfarin]]
**The use of DOACS (e.g. [[Apixaban]]) might be an alternative to [[warfarin]]
*In warfarin-related ICH patients with [[prosthetic valves]]<ref name="pmid21327503">{{cite journal| author=Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, Alexander JH| title=Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. | journal=J Thromb Thrombolysis | year= 2011 | volume= 31 | issue= 4 | pages= 514-22 | pmid=21327503 | doi=10.1007/s11239-011-0574-9 | pmc=3699194 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21327503  }}</ref>
*In warfarin-related ICH patients with [[prosthetic valves]]
**The risk of [[Thromboembolic event|thromboembolic events]] is higher than the risk of recurrent ICH (resumption of [[Oral anticoagulation therapy|OAC]] with [[warfarin]] is often required)
**The risk of [[Thromboembolic event|thromboembolic events]] is higher than the risk of recurrent ICH (resumption of [[Oral anticoagulation therapy|OAC]] with [[warfarin]] is often required)
*The optimal time to resumption of anticoagulation after warfarin-related ICH is unclear and may vary from patient to patient
*The optimal time to resumption of anticoagulation after warfarin-related ICH is unclear and may vary from patient to patient.<ref name="pmid21030703">{{cite journal| author=Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S| title=Optimal timing of resumption of warfarin after intracranial hemorrhage. | journal=Stroke | year= 2010 | volume= 41 | issue= 12 | pages= 2860-6 | pmid=21030703 | doi=10.1161/STROKEAHA.110.593087 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21030703  }}</ref>
*Avoidance of oral anticoagulation (OAC) for 4-8 weeks, in patients without mechanical heart valves, might decrease the risk of ICH recurrence
*Avoidance of oral anticoagulation (OAC) for 4-8 weeks, in patients without mechanical heart valves, might decrease the risk of ICH recurrence
==== Resumption of statins ====
There is '''insufficient''' data to recommend restrictions on use of statin agents.<ref name="pmid16899775">{{cite journal| author=Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE et al.| title=High-dose atorvastatin after stroke or transient ischemic attack. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 6 | pages= 549-59 | pmid=16899775 | doi=10.1056/NEJMoa061894 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16899775  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17203927 Review in: ACP J Club. 2007 Jan-Feb;146(1):7]</ref>
===Prevention of complications===
===Prevention of complications===
The preventive measures which may help prevent complications of intracerebral hemorrhage include:<ref name="pmid20539816" />
The preventive measures which may help prevent complications of intracerebral hemorrhage include:<ref name="ASA/AHA-ICH-Guid2">2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage http://stroke.ahajournals.org/content/early/2015/05/28/STR.0000000000000069 Accessed on November 10, 2016</ref><ref name="pmid20539816" /><ref name="pmid23983842">{{cite journal| author=Armstrong JR, Mosher BD| title=Aspiration pneumonia after stroke: intervention and prevention. | journal=Neurohospitalist | year= 2011 | volume= 1 | issue= 2 | pages= 85-93 | pmid=23983842 | doi=10.1177/1941875210395775 | pmc=3726080 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23983842  }}</ref>
*Use of intermittent pneumatic compression begun as early as the day of hospital admission   
*Use of intermittent pneumatic compression begun as early as the day of hospital admission   
*[[Prophylactic]] anticonvulsant medication has not been demonstrated to be beneficia. However, in a case of  clinical seizures or electrographic seizures in patients with a change in mental status should be treated with antisezure drugs to prevent recurrence
*[[Prophylactic]] anticonvulsant medication has not been demonstrated to be beneficial. However, in a case of  clinical seizures or electrographic seizures in patients with a change in mental status should be treated with antisezure drugs to prevent recurrence
*Proper positioning of patient, and the use of thick feed with the help of nasogastric tube for feeding to prevent aspiration pneumonia in patients with cranial nerve palsies affecting pharyngeal motility and gag reflex
*Proper positioning of patient, and the use of thick feed with the help of nasogastric tube for feeding to prevent aspiration pneumonia in patients with cranial nerve palsies affecting pharyngeal motility and gag reflex
*Pressure ulcers may be prevented by use of air mattress and regular change in position of patient
*Pressure ulcers may be prevented by use of air mattress and regular change in position of patient

Latest revision as of 17:06, 13 December 2016

Intracerebral hemorrhage Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stroke from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Emergency Diagnosis and Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Other Imaging Findings

Treatment

Early Assessment

Management

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage (2015)

Management of ICH

AHA/ASA Guideline Recommendation for the Primary Prevention of Stroke (2014)

Primary Prevention of Stroke

Case Studies

Case #1

Intracerebral hemorrhage secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Intracerebral hemorrhage secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Intracerebral hemorrhage secondary prevention

CDC on Intracerebral hemorrhage secondary prevention

Intracerebral hemorrhage secondary prevention in the news

Blogs on Intracerebral hemorrhage secondary prevention

Directions to Hospitals Treating Stroke

Risk calculators and risk factors for Intracerebral hemorrhage secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]

Overview

Effective measures for the secondary prevention of intracerebral hemorrhage include life style modification, treatment of modifiable risk factors such as blood pressure control and anticoagulation medication avoidance, and enforcing the measures to prevent the complications.[1][2][3][4][5][6][7]

Secondary prevention

Prevention of recurrent ICH

Life style modification

Life style modification measures which may help reduce the risk of intracerebral hemorrhage recurrent may include:[1][2]

  • Eating healthy balanced diet
  • Smoking cessation
  • Decreased alcohol intake
  • Improved support from health care providers & care takers
  • Patient education (involvement in BP monitoring to improve adherence to therapy)

Blood pressure control

Receive early treatment targeted to an SBP level <140 mmHg to improve the chances of achieving better functional recovery.[1]

Restarting anticoagulation

Restarting anticoagulation should be avoided, UNLESS the risk of ischemic stroke is MUCH HIGHER than that of recurrent ICH.[3][4][5]

  • In AF patients with warfarin-associated lobar ICH or suspected CAA, the risk ICH recurrence seems higher than thromboembolic events. Therefore, the best management is to discontinue warfarin therapy.
  • In warfarin-related ICH patients with prosthetic valves[8]
  • The optimal time to resumption of anticoagulation after warfarin-related ICH is unclear and may vary from patient to patient.[9]
  • Avoidance of oral anticoagulation (OAC) for 4-8 weeks, in patients without mechanical heart valves, might decrease the risk of ICH recurrence

Resumption of statins

There is insufficient data to recommend restrictions on use of statin agents.[10]

Prevention of complications

The preventive measures which may help prevent complications of intracerebral hemorrhage include:[1][6][7]

  • Use of intermittent pneumatic compression begun as early as the day of hospital admission 
  • Prophylactic anticonvulsant medication has not been demonstrated to be beneficial. However, in a case of clinical seizures or electrographic seizures in patients with a change in mental status should be treated with antisezure drugs to prevent recurrence
  • Proper positioning of patient, and the use of thick feed with the help of nasogastric tube for feeding to prevent aspiration pneumonia in patients with cranial nerve palsies affecting pharyngeal motility and gag reflex
  • Pressure ulcers may be prevented by use of air mattress and regular change in position of patient

References

  1. 1.0 1.1 1.2 1.3 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage http://stroke.ahajournals.org/content/early/2015/05/28/STR.0000000000000069 Accessed on November 10, 2016
  2. 2.0 2.1 2014 AHA/ASA Guidelines for the Primary Prevention of Stroke http://stroke.ahajournals.org/content/early/2014/10/28/STR.00000000000000467 Accessed on November 17, 2016
  3. 3.0 3.1 Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review http://dx.doi.org/10.1016/j.thromres.2015.05.001 Accessed on December 1, 2016
  4. 4.0 4.1 Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S; et al. (2011). "Apixaban in patients with atrial fibrillation". N Engl J Med. 364 (9): 806–17. doi:10.1056/NEJMoa1007432. PMID 21309657. Review in: Evid Based Med. 2011 Dec;16(6):187-8 Review in: Ann Intern Med. 2011 Apr 19;154(8):JC4-3
  5. 5.0 5.1 Eckman, Mark H., et al. "Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis." Stroke 34.7 (2003): 1710-1716.
  6. 6.0 6.1
  7. 7.0 7.1 Armstrong JR, Mosher BD (2011). "Aspiration pneumonia after stroke: intervention and prevention". Neurohospitalist. 1 (2): 85–93. doi:10.1177/1941875210395775. PMC 3726080. PMID 23983842.
  8. Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, Alexander JH (2011). "Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician". J Thromb Thrombolysis. 31 (4): 514–22. doi:10.1007/s11239-011-0574-9. PMC 3699194. PMID 21327503.
  9. Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S (2010). "Optimal timing of resumption of warfarin after intracranial hemorrhage". Stroke. 41 (12): 2860–6. doi:10.1161/STROKEAHA.110.593087. PMID 21030703.
  10. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE; et al. (2006). "High-dose atorvastatin after stroke or transient ischemic attack". N Engl J Med. 355 (6): 549–59. doi:10.1056/NEJMoa061894. PMID 16899775. Review in: ACP J Club. 2007 Jan-Feb;146(1):7


Template:WS Template:WH